DE50205438D1 - Verwendung von buprenorphin zur therapie der harninkontinenz - Google Patents

Verwendung von buprenorphin zur therapie der harninkontinenz

Info

Publication number
DE50205438D1
DE50205438D1 DE50205438T DE50205438T DE50205438D1 DE 50205438 D1 DE50205438 D1 DE 50205438D1 DE 50205438 T DE50205438 T DE 50205438T DE 50205438 T DE50205438 T DE 50205438T DE 50205438 D1 DE50205438 D1 DE 50205438D1
Authority
DE
Germany
Prior art keywords
buprenorphine
incontinence
harness
therapy
increased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE50205438T
Other languages
German (de)
English (en)
Inventor
Johannes Bartholomaeus
Thomas Christoph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001107828 external-priority patent/DE10107828A1/de
Priority claimed from DE20115429U external-priority patent/DE20115429U1/de
Priority claimed from DE2001162704 external-priority patent/DE10162704A1/de
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to DE50205438T priority Critical patent/DE50205438D1/de
Application granted granted Critical
Publication of DE50205438D1 publication Critical patent/DE50205438D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE50205438T 2001-02-16 2002-02-18 Verwendung von buprenorphin zur therapie der harninkontinenz Expired - Lifetime DE50205438D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE50205438T DE50205438D1 (de) 2001-02-16 2002-02-18 Verwendung von buprenorphin zur therapie der harninkontinenz

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE2001107828 DE10107828A1 (de) 2001-02-16 2001-02-16 Verwendung von Buprenorphin zur Therapie der Harninkontinenz
DE20115429U DE20115429U1 (de) 2001-09-18 2001-09-18 Opioide in der Harninkontinenz
DE2001162704 DE10162704A1 (de) 2001-12-19 2001-12-19 Verwendung von Buprenorphin zur Therapie der Harninkontinenz
DE50205438T DE50205438D1 (de) 2001-02-16 2002-02-18 Verwendung von buprenorphin zur therapie der harninkontinenz
PCT/EP2002/001699 WO2002066031A1 (de) 2001-02-16 2002-02-18 Verwendung von buprenorphin zur therapie der harninkontinenz

Publications (1)

Publication Number Publication Date
DE50205438D1 true DE50205438D1 (de) 2006-02-02

Family

ID=27214302

Family Applications (1)

Application Number Title Priority Date Filing Date
DE50205438T Expired - Lifetime DE50205438D1 (de) 2001-02-16 2002-02-18 Verwendung von buprenorphin zur therapie der harninkontinenz

Country Status (14)

Country Link
US (1) US20040102468A1 (https=)
EP (1) EP1368023B1 (https=)
JP (1) JP4908726B2 (https=)
AT (1) ATE314066T1 (https=)
AU (1) AU2002242705B2 (https=)
CA (1) CA2438339C (https=)
DE (1) DE50205438D1 (https=)
DK (1) DK1368023T3 (https=)
ES (1) ES2255607T3 (https=)
HU (1) HU229354B1 (https=)
MX (1) MXPA03006742A (https=)
NZ (1) NZ528064A (https=)
PL (1) PL204638B1 (https=)
WO (1) WO2002066031A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323421A1 (en) * 2001-12-20 2003-07-02 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
US8260389B2 (en) * 2003-10-15 2012-09-04 Hegln (Dalian) Pharmaceuticals, Inc. Bladder function monitoring methods, apparatuses, media and signals
EP1682002A4 (en) 2003-10-15 2010-03-31 Univ British Columbia METHOD AND DEVICE FOR URODYNAMIC ANALYSIS
JP6370802B2 (ja) * 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
EP3067357A1 (en) 2015-03-11 2016-09-14 Siegfried AG Method of manufacturing stereoisomers of buprenorphine and analogues thereof
CN107320770A (zh) * 2017-07-12 2017-11-07 江苏西宏生物医药有限公司 一种注射植入剂
EP4613751A1 (en) 2024-03-07 2025-09-10 Siegfried AG Method of making chemical compounds useful for the synthesis of buprenorphine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
DE69631525T2 (de) * 1995-03-03 2004-12-16 Endo Pharmaceuticals Inc. Verwendung von dextromethorphan oder dextrorphan zur behandlung der harninkontinenz
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
IT1302682B1 (it) * 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina

Also Published As

Publication number Publication date
JP2004525900A (ja) 2004-08-26
EP1368023A1 (de) 2003-12-10
HU229354B1 (en) 2013-11-28
MXPA03006742A (es) 2003-10-24
CA2438339C (en) 2010-12-14
DK1368023T3 (da) 2006-02-13
NZ528064A (en) 2006-03-31
PL204638B1 (pl) 2010-01-29
ATE314066T1 (de) 2006-01-15
US20040102468A1 (en) 2004-05-27
WO2002066031A1 (de) 2002-08-29
HUP0302984A3 (en) 2006-02-28
CA2438339A1 (en) 2002-08-29
JP4908726B2 (ja) 2012-04-04
EP1368023B1 (de) 2005-12-28
AU2002242705B2 (en) 2006-08-24
PL367401A1 (en) 2005-02-21
ES2255607T3 (es) 2006-07-01
HUP0302984A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
WO2003080582A3 (de) Fredericamycin-derivate
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
MY140169A (en) Compounds, compositions, and methods
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
MXPA05008478A (es) Heterociclos sustituidos.
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
UA72948C2 (uk) Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
BR0312446A (pt) 2-heteroaril carboxamidas
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
AU2003252025A8 (en) Compounds, compositions, and methods
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
DE50205438D1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
MXPA02001204A (es) Compuestos calciliticos.
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE50313329D1 (de) 1-phenyl-2-dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition